Pirfenidone (DB04951): A Comprehensive Monograph on its Pharmacology, Clinical Efficacy, and Therapeutic Role in Fibrotic Lung Disease

Executive Summary

Pirfenidone represents a landmark therapeutic advance in the management of fibrotic lung disease, specifically Idiopathic Pulmonary Fibrosis (IPF). As a first-in-class, orally administered pyridone derivative, it has fundamentally shifted the treatment paradigm for IPF from purely supportive care to active disease modification.[1] The primary approved indication for Pirfenidone is the treatment of adults with IPF, a chronic, relentlessly progressive, and ultimately fatal interstitial pneumonia characterized by the formation of scar tissue in the lungs.[1]

The therapeutic benefit of Pirfenidone is derived from a pleiotropic mechanism of action that, while not yet fully elucidated, is understood to encompass a combination of antifibrotic, anti-inflammatory, and antioxidant properties.[1] Its activity is primarily mediated through the downregulation of key profibrotic and pro-inflammatory signaling pathways, most notably those involving Transforming Growth Factor-beta 1 (TGF-β1) and Tumor Necrosis Factor-alpha (TNF-α).[1] This modulation results in the inhibition of fibroblast proliferation, their differentiation into myofibroblasts, and the subsequent reduction in excessive collagen and extracellular matrix deposition, which are the pathological hallmarks of fibrosis.[1]

The clinical efficacy of Pirfenidone was established in a robust program of Phase 3 clinical trials, including the pivotal ASCEND and two CAPACITY studies. These trials demonstrated that Pirfenidone significantly slows the rate of lung function decline, as measured by Forced Vital Capacity (FVC), compared to placebo.[10] Furthermore, pre-specified pooled analyses of these trials revealed a statistically significant mortality benefit, with Pirfenidone reducing the risk of all-cause mortality by 48% at one year, elevating its status from a drug that merely modifies a surrogate endpoint to one that improves survival.[10]

The safety profile of Pirfenidone is well-characterized and considered manageable, although it requires active patient monitoring and education. The most common treatment-emergent adverse events are gastrointestinal (nausea, diarrhea, dyspepsia) and dermatological (rash, photosensitivity).[13] While generally mild to moderate, these side effects can impact adherence, making proactive management crucial for long-term treatment success. More serious but rare risks include drug-induced liver injury (DILI) and severe cutaneous adverse reactions (SCARs), necessitating regular liver function monitoring and patient vigilance.[13]

The pharmacology of Pirfenidone is defined by its extensive hepatic metabolism, with 70-80% being cleared via the cytochrome P450 isoenzyme CYP1A2.[14] This metabolic pathway is the source of clinically significant drug-drug interactions. Co-administration with strong CYP1A2 inhibitors (e.g., fluvoxamine) or moderate inhibitors (e.g., ciprofloxacin) can dramatically increase Pirfenidone exposure, requiring dose adjustments, while strong inducers (e.g., cigarette smoke) can decrease exposure and potentially reduce efficacy.[13]

The therapeutic landscape for IPF continues to evolve. Comparative effectiveness studies against the other approved antifibrotic, nintedanib, suggest similar efficacy in slowing FVC decline but with distinct safety profiles that can guide individualized therapy.[17] The cost-effectiveness of Pirfenidone is highly dependent on the pricing and reimbursement structures of individual national healthcare systems.[19] Future research is focused on expanding its use to other progressive fibrosing lung diseases, exploring its role in combination therapy with nintedanib, and developing novel formulations, such as inhaled Pirfenidone, to improve its therapeutic index by maximizing local lung delivery and minimizing systemic toxicity.[4]

Scientific and Pharmacological Foundation

Physicochemical Characteristics

Pirfenidone is a synthetically derived, small molecule new molecular entity classified as a pyridone.[1] Its chemical identity is 5-methyl-1-phenyl-2-(1H)-pyridone, with the Chemical Abstracts Service (CAS) Number 53179-13-8.[1] The empirical formula for Pirfenidone is

C12​H11​NO, corresponding to a molecular weight of approximately 185.23 Daltons (Da).[15] Its International Union of Pure and Applied Chemistry (IUPAC) name is 5-methyl-1-phenylpyridin-2-one.[25]

In its solid state, Pirfenidone is a white to pale yellow, non-hygroscopic powder.[24] It has a defined melting point of approximately 109°C and does not exhibit polymorphism, which simplifies its formulation and ensures consistent solid-state properties.[24] The solubility profile of Pirfenidone is a critical determinant of its pharmacokinetic behavior. It is sparingly soluble in aqueous media, with a water solubility of 19 mg/mL at 25°C, and is also sparingly soluble in 1.0 N hydrochloric acid (HCl).[24] In contrast, it is freely soluble in organic solvents such as methanol, ethyl alcohol, acetone, and chloroform, indicating a predominantly lipophilic or hydrophobic character.[24]

The combination of its low molecular weight and lipophilic nature is fundamental to its biological activity. This profile allows Pirfenidone to diffuse freely across cellular membranes without the need for a specific transporter or receptor.[3] This ability for passive, widespread intracellular entry provides a compelling explanation for its pleiotropic effects and why its precise molecular mechanism of action has been challenging to fully elucidate. Unlike drugs designed to interact with a single, high-affinity receptor, Pirfenidone can access the intracellular environment of multiple cell types implicated in fibrosis (e.g., fibroblasts, epithelial cells, inflammatory cells) and modulate a variety of signaling pathways simultaneously. This receptor-independent mode of action is a foundational characteristic that links its chemical structure directly to its complex and multifaceted pharmacology, including its observed ability to permeate the blood-brain barrier.[25]

Mechanism of Action: A Multifaceted Antifibrotic Agent

The therapeutic efficacy of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF) stems from a broad spectrum of biological activities, which are collectively described as antifibrotic, anti-inflammatory, and antioxidant.[1] While a single, definitive molecular target has not been identified, extensive research has clarified its modulatory effects on key pathological pathways. The overall clinical benefit is understood to be the integrated result of these pleiotropic actions rather than an effect on one specific target.[1]

The various mechanisms of Pirfenidone are not merely parallel processes but appear to function as a synergistic cascade. Evidence suggests that the drug's antioxidant properties may initiate a chain of events that leads to its ultimate antifibrotic effects.[1] In the lung, oxidative stress is a well-established trigger for inflammation. By mitigating this initial insult through its antioxidant activities, Pirfenidone can subsequently dampen the pro-inflammatory response. This creates a cellular environment that is less conducive to fibrosis, allowing for the downstream modulation of the primary fibrotic signaling pathways.

Antifibrotic Actions

The core antifibrotic activity of Pirfenidone is centered on its ability to modulate the signaling of Transforming Growth Factor-beta 1 (TGF-β1), a master regulator of fibrosis.[1] By attenuating the production and activity of TGF-β1, Pirfenidone interferes with the central pathogenic process in IPF.[1] This leads to several critical downstream effects:

• Inhibition of Fibroblast Proliferation and Myofibroblast Differentiation: Pirfenidone has been shown to reduce the proliferation of lung fibroblasts.[3] Crucially, by suppressing TGF-β1 signaling, it inhibits the differentiation of these fibroblasts into myofibroblasts—the primary cell type responsible for excessive extracellular matrix (ECM) deposition.[1]
• Reduction of Extracellular Matrix Production: Consequently, Pirfenidone downregulates the synthesis of key components of the fibrotic scar, including procollagens I and II, fibronectin, and the collagen-specific chaperone protein, heat shock protein 47 (Hsp47).[1] This directly addresses the pathological accumulation of scar tissue in the lung.

Anti-inflammatory Actions

Pirfenidone exhibits significant anti-inflammatory properties that complement its antifibrotic effects. It modulates the inflammatory milieu that perpetuates the fibrotic process in IPF.[3]

• Suppression of Pro-inflammatory Cytokines: The drug has been shown to reduce the production of multiple pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), and Interferon-gamma (IFN-γ).[1] TNF-α, in particular, is a key pathway regulated by Pirfenidone.[1]
• Modulation of Inflammatory Cell Accumulation: In animal models, Pirfenidone prevents the accumulation of inflammatory cells, such as lymphocytes, macrophages, and neutrophils, at sites of lung injury and inflammation.[1] It has also been shown to promote the production of the anti-inflammatory cytokine IL-10.[1]

Antioxidant Actions

The antioxidant properties of Pirfenidone are thought to be an upstream mechanism contributing to its broader effects.[1] Oxidative stress is a known contributor to cellular damage and inflammation in the lungs of patients with IPF. Pirfenidone helps to mitigate this damage through two primary mechanisms:

• Scavenging of Reactive Oxygen Species (ROS): In vitro studies have demonstrated that Pirfenidone can directly scavenge harmful ROS, such as hydroxyl radicals, thereby neutralizing their damaging potential.[1]
• Inhibition of Lipid Peroxidation: The drug inhibits NADPH-dependent microsomal lipid peroxidation, a process where ROS attack lipids in cell membranes, leading to cell damage.[1] By preventing this, Pirfenidone helps preserve cellular integrity in the face of oxidative stress.

Clinical Pharmacology: Pharmacokinetics and Pharmacodynamics

The clinical pharmacology of Pirfenidone is characterized by rapid oral absorption, extensive hepatic metabolism primarily via the CYP1A2 enzyme, and a short elimination half-life. These properties dictate its dosing regimen, food-effect recommendations, and its susceptibility to significant drug-drug interactions.

Absorption

Pirfenidone is administered orally and is rapidly absorbed from the gastrointestinal tract.[2] In the fasted state, the time to reach maximum plasma concentration (Tmax) is approximately 0.5 hours.[15] However, the drug's absorption is significantly influenced by the presence of food, a phenomenon that has been leveraged as a key therapeutic strategy. Administration with a meal substantially reduces the rate and extent of absorption, lowering the peak plasma concentration (Cmax) by approximately 50% and modestly reducing the overall exposure (Area Under the Curve, AUC).[15]

This "food effect" is not viewed as a pharmacokinetic limitation but rather as a deliberate clinical tool to enhance tolerability. The high incidence of gastrointestinal side effects, particularly nausea and dizziness, is linked to the rapid rise in plasma concentrations seen in the fasted state.[7] By blunting this peak, administration with food significantly reduces the frequency of these adverse events.[15] This practice is a classic example of optimizing a drug's therapeutic index, where a slight reduction in bioavailability is accepted in exchange for a marked improvement in patient tolerability and, consequently, better long-term adherence to a chronic therapy.[23]

Distribution

Pirfenidone binds moderately to human plasma proteins, with a binding range of 50% to 62%, primarily to serum albumin.[1] The mean apparent oral steady-state volume of distribution is approximately 59 to 71 liters, indicating that the drug is not extensively distributed into tissues but rather undergoes modest distribution.[1]

Metabolism

Pirfenidone undergoes extensive first-pass metabolism in the liver.[15] This metabolic clearance is predominantly mediated by the cytochrome P450 (CYP) enzyme system. The primary metabolic pathway, accounting for 70-80% of Pirfenidone's metabolism, is oxidation by the CYP1A2 isoenzyme.[1] Other CYP isoenzymes, including CYP2C9, 2C19, 2D6, and 2E1, make minor contributions.[1]

This heavy reliance on a single primary metabolic enzyme (CYP1A2) makes Pirfenidone highly vulnerable to clinically significant drug-drug interactions with substances that inhibit or induce this enzyme. The major metabolite formed through this process is 5-carboxy-pirfenidone, which is considered pharmacologically inactive or to have only very weak activity.[1] In plasma, only the parent drug and the 5-carboxy metabolite are present in significant quantities.[1]

Excretion

Following its rapid metabolism, Pirfenidone is cleared quickly from the body. It has a mean terminal elimination half-life of approximately 2.4 to 3 hours in healthy subjects.[1] Approximately 80% of an orally administered dose is excreted in the urine within 24 hours.[1] The vast majority of the excreted drug (over 95%) is in the form of the inactive 5-carboxy-pirfenidone metabolite, with less than 1% of the dose being excreted as the unchanged parent drug.[1]

Evidence from Clinical Trials: From Bench to Bedside

Preclinical Evidence in Fibrosis Models

The clinical development of Pirfenidone was built upon a strong foundation of preclinical evidence demonstrating its consistent antifibrotic activity across various animal models of fibrosis. These studies were crucial in establishing the scientific rationale for investigating the drug in human fibrotic diseases.[7] Pirfenidone was shown to reduce both biochemical and histopathological indices of fibrosis not only in the lung but also in the liver, heart, and kidney, suggesting a systemic antifibrotic potential.[7]

The most widely used and informative of these was the bleomycin-induced pulmonary fibrosis model. In this model, administration of the chemotherapeutic agent bleomycin induces oxidative stress and acute inflammation in the lungs of animals, which is followed by the progressive development of fibrosis that mimics many aspects of human IPF.[7] Numerous studies in this model consistently showed that Pirfenidone could attenuate bleomycin-induced pulmonary fibrosis.[7] Importantly, the drug was found to be effective under two different treatment paradigms. When administered prophylactically (concurrently with the bleomycin-induced lung injury), Pirfenidone minimized early lung edema and subsequent fibrosis.[7] When administered therapeutically (after fibrosis was already established and progressing), it still demonstrated a significant antifibrotic effect, reducing the expression of fibrogenic mediators and halting further scar formation.[7] This preclinical evidence was instrumental in supporting its progression into human clinical trials for IPF.

Pivotal Phase 3 Trials in Idiopathic Pulmonary Fibrosis (IPF)

The cornerstone of evidence for Pirfenidone's efficacy in IPF comes from three large, multinational, randomized, double-blind, placebo-controlled Phase 3 trials: CAPACITY 004 (NCT00287716), CAPACITY 006 (NCT00287729), and ASCEND (NCT01366209).[5] These trials were designed to evaluate the efficacy and safety of oral Pirfenidone at a dose of 2403 mg/day in patients with mild-to-moderate IPF, defined by a Forced Vital Capacity (FVC) between 50% and 90% of the predicted value.[11]

The two concurrent CAPACITY trials yielded conflicting results for the primary endpoint of change in percent predicted FVC at week 72. While study 004 demonstrated a statistically significant benefit for Pirfenidone, study 006 did not meet this primary endpoint.[10] This discrepancy prompted the need for a third, confirmatory Phase 3 trial, ASCEND.[11]

The ASCEND trial successfully confirmed the efficacy of Pirfenidone. It met its primary endpoint, demonstrating that treatment with Pirfenidone significantly reduced the decline in lung function over 52 weeks. Specifically, Pirfenidone resulted in a 47.9% relative reduction in the proportion of patients who experienced a clinically meaningful decline in FVC of ≥10% or death compared to placebo.[10] Furthermore, Pirfenidone demonstrated significant treatment effects on the two key secondary endpoints:

• Progression-Free Survival (PFS): Pirfenidone reduced the risk of disease progression or death by 43% compared to placebo.[10]
• 6-Minute Walk Test Distance (6MWD): Pirfenidone reduced by 27.5% the proportion of patients who experienced a significant decline (≥50 meters) in exercise tolerance.[10]

These robust findings from ASCEND, in conjunction with the positive data from CAPACITY 004, solidified the evidence base for Pirfenidone's approval and established it as a standard of care for IPF.

Table 1: Summary of Pivotal Phase 3 Clinical Trials (CAPACITY & ASCEND)
Trial Name
NCT Identifier
Patient Population (N)
Treatment Duration
Primary Endpoint
Primary Endpoint Result (Pirfenidone vs. Placebo)
Key Secondary Endpoint Results
Data sourced from.5

Pooled Analyses and Mortality Data

While individual clinical trials provide essential data, their statistical power can be limited for less frequent events like mortality, especially within the typical 1- to 2-year study duration of IPF trials.[10] The relatively low number of deaths observed in any single trial makes it difficult to detect a statistically significant difference between treatment and placebo groups, even if a true survival benefit exists. This was the case in the ASCEND trial, where a numerical trend toward reduced mortality was observed but did not reach statistical significance on its own.[10]

To overcome this limitation, a pre-specified pooled analysis of the combined patient population from the ASCEND and CAPACITY trials (N=1,247) was conducted. By increasing the total number of patients and observed events, this analysis provided greater statistical power to more precisely estimate the effect of Pirfenidone on survival.[10] The results of this pooled analysis were profound and clinically transformative. The analysis demonstrated that treatment with Pirfenidone was associated with a statistically significant 48% reduction in the risk of all-cause mortality at one year compared to placebo (Hazard Ratio 0.52).[10] Furthermore, the risk of treatment-emergent, IPF-related death was reduced by an even greater margin of 68% (HR 0.32).[10]

This finding elevated the clinical narrative of Pirfenidone. It was no longer simply a drug that could slow the decline of a surrogate marker of lung function (FVC); it was now a therapy proven to improve survival, a hard clinical endpoint of paramount importance to both patients and clinicians. This mortality benefit has become a central pillar of its value proposition in the management of this fatal disease.

Real-World Evidence and Post-Marketing Experience

Following regulatory approval, the evaluation of Pirfenidone transitioned from the highly controlled environment of randomized controlled trials (RCTs) to the more heterogeneous setting of routine clinical practice. This has generated a wealth of real-world evidence from long-term open-label extension studies, post-authorization safety registries, and observational cohort studies, which provide critical insights into the drug's long-term effectiveness and safety in a broader patient population.

Key sources of this evidence include the RECAP open-label extension study, which followed patients from the CAPACITY and ASCEND trials for up to 9.9 years, and the PASSPORT registry, a large, prospective, observational study conducted in Europe.[10] These studies, along with numerous single-center and national observational reports, have largely confirmed the safety profile established in the pivotal trials, with no new, unexpected safety signals emerging over long-term use.[12]

However, a consistent finding from real-world data is the presence of an "efficacy-effectiveness gap." While the types of adverse events are the same as those seen in RCTs, their reported incidence and the resulting rates of dose modification and treatment discontinuation are often higher in clinical practice.[4] For instance, in the PASSPORT registry, 28.7% of patients discontinued treatment due to an adverse drug reaction, a rate higher than that observed in the pivotal trials.[41] This underscores a critical clinical reality: the benefits of Pirfenidone observed in RCTs can only be achieved in practice if patients are able to adhere to the therapy long-term. This highlights the paramount importance of proactive and effective management of side effects to help patients remain on treatment and derive its full, long-term benefits.

Clinical Application and Patient Management

Dosing, Administration, and Therapeutic Monitoring

The clinical use of Pirfenidone requires a specific dose-titration schedule to optimize tolerability, strict adherence to administration with food, and regular laboratory monitoring to ensure safety.

The standard dosing regimen for Pirfenidone begins with a 2-week dose-escalation period. Treatment is initiated at a dose of 267 mg three times daily (total 801 mg/day) for the first 7 days. In the second week (days 8-14), the dose is increased to 534 mg three times daily (total 1602 mg/day). From day 15 onwards, the full maintenance dose of 801 mg three times daily (total 2403 mg/day) is administered.[2] This gradual titration is designed to improve gastrointestinal tolerability as the patient acclimates to the medication. If a patient misses 14 or more consecutive days of treatment, therapy must be re-initiated with the 2-week titration schedule.[2]

It is a critical clinical directive that Pirfenidone be taken with food.[2] As previously discussed, this practice mitigates the incidence and severity of nausea and dizziness by blunting the peak plasma concentration of the drug.[7]

To monitor for potential hepatotoxicity, a serious but rare adverse event, regular laboratory monitoring of liver function is mandatory. Liver function tests (LFTs), including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin, must be conducted prior to initiating therapy, then monthly for the first 6 months of treatment, and every 3 months thereafter. LFTs should also be performed promptly if a patient reports any symptoms suggestive of liver injury, such as fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice.[13]

Safety and Tolerability Profile

The safety and tolerability profile of Pirfenidone has been well-characterized through its extensive clinical trial program and post-marketing surveillance. While generally considered manageable, the drug is associated with a distinct set of common adverse events (AEs) and rare but serious risks that require diligent monitoring and patient education.

Common Adverse Events

The most frequently reported AEs associated with Pirfenidone are gastrointestinal and dermatological in nature. Pooled data from the Phase 3 trials show a significantly higher incidence of these events in the Pirfenidone group compared to placebo.[13]

• Gastrointestinal Disorders: These are the most common AEs and often occur early in treatment. They include nausea (36%), diarrhea (26%), dyspepsia (19%), abdominal pain (24%), vomiting (13%), and decreased appetite/anorexia (13%).[7]
• Skin-Related Reactions: These are also very common and include rash (30%) and photosensitivity reactions (9%).[7] Photosensitivity can manifest as an exaggerated sunburn reaction upon exposure to sunlight.
• Other Common AEs (≥10%): Other frequently reported events include fatigue, headache, dizziness, upper respiratory tract infection, gastroesophageal reflux disease (GERD), and weight loss.[13]

Serious Adverse Events

While less common, there are several serious risks associated with Pirfenidone that necessitate immediate medical attention and specific monitoring protocols.

• Drug-Induced Liver Injury (DILI): Elevations in liver enzymes (ALT/AST) are more common with Pirfenidone than placebo (3.7% vs 0.8% for ≥3x ULN).[13] In the post-marketing period, serious cases of DILI, including severe liver injury with fatal outcomes, have been reported. This risk underscores the importance of the mandated LFT monitoring schedule.[13]
• Severe Cutaneous Adverse Reactions (SCARs): Rare but life-threatening skin reactions, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported in the post-marketing setting. Patients should be counseled to report any severe rash, blistering, or mucosal sores immediately. If a SCAR is confirmed, Pirfenidone must be permanently discontinued.[13]
• Angioedema: Cases of angioedema (swelling of the face, lips, tongue, or throat) have been reported and can be serious. Pirfenidone is contraindicated in patients with a history of angioedema related to the drug.[14]

Table 2: Incidence of Common and Serious Adverse Events with Pirfenidone (Pooled Phase 3 Data)
Adverse Reaction
Nausea
Rash
Diarrhea
Fatigue
Dyspepsia
Dizziness
Vomiting
Decreased Appetite / Anorexia
Photosensitivity Reaction
Elevated ALT/AST (≥3x ULN)
Data sourced from.13 Abdominal pain, upper respiratory tract infection, and headache also had high incidence but with smaller differences versus placebo.

Management of Common Adverse Events

The long-term benefits of Pirfenidone, such as slowed disease progression and improved survival, are contingent upon continuous, long-term use. However, the high incidence of adverse events can lead to dose reductions, interruptions, or permanent discontinuation, thereby compromising the drug's real-world effectiveness. Therefore, the proactive and effective management of side effects is not merely a matter of patient comfort; it is a core component of achieving the therapeutic goals of the treatment. A strong patient-provider partnership focused on education, prevention, and active management is essential.

• Management of Gastrointestinal Events: To mitigate GI side effects, patients must be counseled to always take Pirfenidone with food, and some may find it helpful to divide the dose throughout the meal.[12] If symptoms like nausea or diarrhea persist, a temporary dose reduction or a treatment interruption of 1-2 weeks, followed by a gradual re-titration, can often improve tolerability. In some cases, adjunctive use of antiemetics or other gastrointestinal agents may be considered.[12]
• Management of Photosensitivity and Rash: Patient education is the cornerstone of managing skin-related AEs. Before starting therapy, patients must be instructed on the importance of strict sun avoidance. This includes avoiding direct sunlight and sunlamps, consistently using a broad-spectrum (UVA/UVB) sunscreen with an SPF of 50 or higher, and wearing protective clothing and sunglasses when outdoors.[2] For a mild-to-moderate photosensitivity reaction or rash, a temporary dose reduction may be sufficient. If the reaction is more severe or persistent, treatment should be interrupted. Once the reaction resolves, the dose can be carefully re-escalated as tolerated.[12]

Clinically Significant Drug Interactions

Pirfenidone's heavy reliance on the CYP1A2 enzyme for its metabolic clearance makes it highly susceptible to clinically significant drug-drug interactions. Prescribers and pharmacists must conduct a thorough medication review before initiating therapy and remain vigilant for changes in concomitant medications throughout the course of treatment.

Interactions with CYP1A2 Inhibitors

Inhibitors of CYP1A2 can significantly decrease the metabolism of Pirfenidone, leading to increased plasma concentrations and a higher risk of adverse reactions.

• Strong Inhibitors: Co-administration with strong CYP1A2 inhibitors is not recommended. The antidepressant fluvoxamine, a potent inhibitor, has been shown to increase Pirfenidone's overall exposure (AUC) by approximately 400%.[16] If the use of a strong inhibitor like fluvoxamine or the antibiotic enoxacin is unavoidable, the Pirfenidone dose must be reduced to 267 mg three times daily (801 mg/day total).[13]
• Moderate Inhibitors: Co-administration with moderate CYP1A2 inhibitors also requires caution and dose adjustment. The antibiotic ciprofloxacin, when used at a dose of 750 mg twice daily, increases Pirfenidone exposure by 81%. In this situation, the Pirfenidone dose should be reduced to 534 mg three times daily (1602 mg/day total).[14] Patients should be monitored closely when using lower doses of ciprofloxacin.
• Combined Inhibitors: Agents that inhibit both CYP1A2 and one or more of the other minor CYP pathways involved in Pirfenidone metabolism should be avoided.[14]

Interactions with CYP1A2 Inducers

Inducers of CYP1A2 can accelerate the metabolism of Pirfenidone, leading to lower plasma concentrations and a potential loss of efficacy.

• Strong Inducers: The most common and clinically relevant strong CYP1A2 inducer is cigarette smoke. Smoking has been shown to decrease Pirfenidone exposure.[16] Therefore, patients should be strongly counseled to stop smoking prior to starting Pirfenidone and to avoid smoking throughout the treatment period. Concomitant use of other strong CYP1A2 inducers should be avoided.[13]

Table 3: Clinically Significant Drug Interactions and Recommended Dose Management
Interacting Drug/Substance
Fluvoxamine, Enoxacin
Ciprofloxacin (750 mg BID)
Amiodarone, Propafenone
Cigarette Smoke
Grapefruit Juice
Data sourced from.13 TID = three times daily; BID = twice daily.

Patient-Reported Outcomes and Quality of Life

While the primary endpoint of the pivotal clinical trials for Pirfenidone was the change in FVC, a measure of lung function, it is equally important to understand the drug's impact on the patient's subjective experience of the disease. Patient-reported outcomes (PROs) and measures of health-related quality of life (HRQoL) provide critical insight into how a treatment affects symptoms, daily functioning, and overall well-being.

Several studies have evaluated these patient-centric endpoints using validated instruments. The PNEUMON study (NCT03115619) was a post-marketing observational study specifically designed to evaluate the change in quality of life, as assessed by the Saint George’s Respiratory Questionnaire (SGRQ), as its primary outcome.[48] The SGRQ is a comprehensive questionnaire that measures the impact of respiratory disease on overall health, daily life, and perceived well-being.

A real-world study conducted in Taiwan provided valuable data on this topic. In this study of 50 patients with IPF, treatment with Pirfenidone over 12 months was associated with a slight but statistically significant improvement in quality of life.[31] The researchers observed improvements in the scores of both the SGRQ and the COPD Assessment Test (CAT), another validated tool for assessing the impact of respiratory symptoms. The mean SGRQ scores improved significantly between 3 and 6 months of therapy, and the improvement in CAT scores was observed at 3 months and persisted for the 12-month duration of the study.[31] These findings suggest that by stabilizing lung function and preventing disease progression, Pirfenidone can also lead to tangible benefits in how patients feel and function in their daily lives.

Comparative and Economic Analysis

Comparative Efficacy and Safety: Pirfenidone vs. Nintedanib

Since 2014, the treatment landscape for IPF has been defined by the availability of two approved antifibrotic agents: Pirfenidone and nintedanib. As no large-scale, head-to-head randomized trials have been conducted, clinicians rely on network meta-analyses of the respective placebo-controlled trials and real-world observational studies to make comparative assessments. These analyses indicate that both drugs are effective in slowing disease progression but possess distinct efficacy and safety profiles that are crucial for individualized treatment decisions.

Comparative Efficacy

Network meta-analyses consistently show that both Pirfenidone and nintedanib are significantly more effective than placebo at reducing the rate of FVC decline over one year.[17] Some analyses suggest potential differences in other key endpoints. For instance, one network meta-analysis found that Pirfenidone significantly reduced the odds of a patient experiencing a ≥10% decline in predicted FVC compared to placebo, whereas the evidence for nintedanib on this categorical endpoint was not conclusive.[18] The same analysis indicated that Pirfenidone reduced all-cause mortality relative to placebo, while a statistically significant difference was not found for nintedanib.[18]

Real-world evidence has provided further comparative insights, particularly regarding healthcare utilization. A large retrospective study of US Medicare beneficiaries found that patients initiating Pirfenidone had a significantly lower risk of both all-cause hospitalization (21% reduction) and respiratory-related hospitalization (20% reduction) compared to those initiating nintedanib.[49] This finding suggests a potential advantage for Pirfenidone in reducing the burden of acute events that lead to hospital admission.

Comparative Safety

The most pronounced differences between the two drugs lie in their safety and tolerability profiles. This distinction is often the primary driver of treatment selection for a particular patient.

• Pirfenidone: The safety profile is dominated by gastrointestinal events (particularly nausea and dyspepsia) and skin-related events (rash and photosensitivity).[4]
• Nintedanib: The primary and most frequent adverse event is diarrhea, which can be severe in some patients. Liver enzyme elevations are also a shared concern for both drugs.[17]

The differing AE profiles allow for a tailored approach. A patient with a history of significant gastroesophageal reflux or high sun exposure might be a better candidate for nintedanib, whereas a patient with a history of difficult-to-manage diarrhea might be better suited for Pirfenidone.

Table 4: Comparative Efficacy and Safety of Pirfenidone vs. Nintedanib (from Indirect Analyses)
Endpoint
FVC Decline
All-Cause Mortality
Hospitalization Risk
Primary Adverse Events
Primary Metabolism
Data sourced from.17

Health Economics and Cost-Effectiveness

The introduction of effective but high-cost antifibrotic therapies has significant economic implications, both for healthcare systems and for patients. The economic burden of IPF is substantial even without drug costs, driven by frequent hospitalizations, emergency department visits, oxygen therapy, and the management of numerous comorbidities.[51] The annual direct medical costs for a patient with IPF are significantly higher than for matched controls, with inpatient services accounting for a large portion of this expenditure.[52]

The cost-effectiveness of Pirfenidone has been evaluated in numerous studies, but the conclusions are highly dependent on the perspective and willingness-to-pay (WTP) threshold of the specific national healthcare system being analyzed. This variability is driven almost entirely by the vast differences in drug pricing across countries.

• United States: In the U.S., where the annual list price of antifibrotics exceeds $110,000, analyses have concluded that neither Pirfenidone nor nintedanib is considered cost-effective.[19] One U.S.-based study calculated an incremental cost-effectiveness ratio (ICER) of over $1.6 million per quality-adjusted life year (QALY) gained compared to symptom management, a figure far exceeding typical WTP thresholds.[19]
• United Kingdom: The National Institute for Health and Care Excellence (NICE) in the UK recommends Pirfenidone as an option for IPF, but only on the condition that the manufacturer provides it with a confidential discount via a patient access scheme.[55] This indicates that at its list price, the drug would not meet the UK's cost-effectiveness threshold, but the negotiated discount makes it an acceptable value.
• France and Belgium: The picture in other European countries is also mixed and appears to be influenced by local pricing and the specific models used. One analysis from a French perspective found Pirfenidone to be dominant over nintedanib (i.e., more effective and less costly) and cost-effective compared to best supportive care.[20] Conversely, a study from a Belgian perspective found nintedanib to be more cost-saving than Pirfenidone.[57]

This divergence in findings illustrates a critical point: the clinical value of Pirfenidone in slowing a fatal disease is well-established, but its economic value is not universal. It is a direct function of the price negotiated within a given healthcare system.

Future Horizons and Unmet Needs

While Pirfenidone has revolutionized the treatment of IPF, significant unmet needs remain. Research is actively exploring ways to build upon this foundation by expanding its use to other diseases, combining it with other therapies, and developing novel formulations to improve its therapeutic index.

Emerging Therapeutic Indications

The success of Pirfenidone in IPF has spurred investigation into its potential as a broad-spectrum antifibrotic agent for other progressive fibrosing interstitial lung diseases (PF-ILDs) that share common pathological pathways.[21] Evidence is emerging for its use in several conditions:

• Systemic Sclerosis-Associated ILD (SSc-ILD): A Phase 3 clinical trial (NCT03856853) is evaluating the efficacy and safety of Pirfenidone in this population.[59]
• Unclassifiable Interstitial Lung Disease (uILD): In 2019, the FDA granted Breakthrough Therapy Designation for Pirfenidone in uILD, recognizing the potential for it to address a serious unmet need.[60]
• Other PF-ILDs: Studies are exploring its role in conditions like chronic hypersensitivity pneumonitis and connective tissue disease-associated ILDs.[21]
• Post-COVID-19 Pulmonary Fibrosis: Given its established antifibrotic and anti-inflammatory mechanisms, there is a strong rationale for investigating Pirfenidone as a treatment to mitigate the development of pulmonary fibrosis in patients recovering from severe COVID-19 pneumonia.[21]

Combination Antifibrotic Therapy

A logical next step in improving outcomes for IPF patients is to combine the two approved antifibrotic agents, Pirfenidone and nintedanib. The rationale is compelling: the drugs have distinct, non-overlapping mechanisms of action, suggesting that their effects could be additive or even synergistic.[64]

Initial clinical trials have explored this concept. The INJOURNEY trial was an open-label, randomized study that assessed the safety of adding Pirfenidone to ongoing nintedanib therapy.[22] While the study was primarily designed to assess safety, it produced a tantalizing exploratory efficacy signal: patients in the combination therapy arm had a mean FVC change of -13.3 mL over 12 weeks, compared to -40.9 mL in the nintedanib monotherapy arm.[22]

However, the primary barrier to widespread adoption of oral combination therapy is tolerability. The INJOURNEY trial also revealed a very high rate of gastrointestinal adverse events (69.8%) in the combination group, and 35.8% of patients discontinued the add-on Pirfenidone due to side effects.[22] Real-world studies have confirmed that combination therapy leads to a higher incidence of diarrhea compared to monotherapy.[64] This demonstrates that while the combination may offer enhanced efficacy, the cumulative toxicity of administering both oral drugs simultaneously is a major challenge. The future of combination therapy is therefore intrinsically linked to the development of better-tolerated formulations.

Novel Formulations and Delivery Systems

The most promising avenue for improving Pirfenidone's therapeutic index—that is, maximizing its efficacy while minimizing its toxicity—is the development of novel delivery systems. The leading strategy is the creation of an inhaled formulation of Pirfenidone (investigational name AP01).[4]

This approach is a direct scientific response to the problem of systemic side effects that limit the use of the oral drug. By delivering the drug directly to the lungs via a nebulizer, an inhaled formulation aims to achieve high concentrations at the site of disease while dramatically reducing systemic exposure. Early-phase clinical data are highly encouraging. A Phase 1 study showed that inhaled Pirfenidone achieved 35-fold higher concentrations in the epithelial lining fluid of the lung with only 1/15th of the systemic exposure compared to the standard oral dose.[4] This pharmacokinetic profile holds the potential to significantly reduce the dose-limiting gastrointestinal and skin-related side effects, making the drug more tolerable for more patients. A well-tolerated inhaled Pirfenidone could not only improve adherence to monotherapy but could also be the key to unlocking the potential of effective and tolerable combination antifibrotic regimens in the future.

Synthesis and Expert Recommendations

Pirfenidone stands as a foundational therapy in the modern management of Idiopathic Pulmonary Fibrosis. Its approval marked a paradigm shift, moving the treatment goal from merely supportive care to active modification of the disease process. The body of evidence from rigorous clinical trials and extensive real-world use confirms that Pirfenidone provides clinically meaningful benefits, most notably by slowing the progressive loss of lung function and, in pooled analyses, demonstrating a significant survival advantage. Its multifaceted mechanism, which combines antifibrotic, anti-inflammatory, and antioxidant actions, addresses the core pathological drivers of this devastating disease.

However, realizing these benefits in clinical practice requires a nuanced understanding of the drug's properties and a commitment to active patient management. The following expert recommendations are provided for clinicians to optimize the use of Pirfenidone.

Expert Recommendations for Clinicians:

1. Consider Early Initiation of Therapy: IPF is a disease with an unpredictable trajectory. Given the robust evidence that Pirfenidone slows disease progression and the inability to predict which patients will decline rapidly, a "watchful waiting" approach is generally discouraged. For patients with a confirmed diagnosis of IPF and mild-to-moderate disease severity (e.g., FVC ≥50% predicted), therapy with an antifibrotic agent like Pirfenidone should be discussed and considered at the time of diagnosis to preserve lung function for as long as possible.
2. Prioritize Proactive Adverse Event Management: The success of long-term Pirfenidone therapy is inextricably linked to the successful management of its side effects. Patient adherence is paramount, and it is directly threatened by unmanaged gastrointestinal and photosensitivity reactions. Clinicians must engage in comprehensive patient education before treatment initiation, emphasizing the importance of taking the medication with food and adhering to strict sun protection measures. Regular follow-up and a willingness to employ evidence-based management strategies, including temporary dose reductions and interruptions, are critical to helping patients remain on therapy and achieve its long-term benefits.
3. Maintain Vigilance for Drug Interactions: The metabolism of Pirfenidone via CYP1A2 is its Achilles' heel. A meticulous review of all concomitant medications, including over-the-counter drugs and supplements, is mandatory before starting treatment. Specific attention must be paid to known inhibitors of CYP1A2 (e.g., ciprofloxacin, fluvoxamine) and inducers (e.g., cigarette smoke). Patients must be educated about these interactions, and appropriate dose adjustments must be made as per prescribing guidelines to ensure both safety and efficacy.

Future Research Imperatives:

Despite the progress made, critical questions remain that will shape the next decade of research and clinical practice for fibrotic lung disease.

1. Definitive Combination Therapy Trials: The tantalizing efficacy signal from early combination studies must be confirmed in a large-scale, randomized, placebo-controlled trial. The central question is whether a combination regimen, likely involving a novel formulation like inhaled Pirfenidone to ensure tolerability, can provide superior efficacy over monotherapy and become the new standard of care for IPF.
2. Validation in Expanded Indications: The potential for Pirfenidone to serve as a broad-spectrum antifibrotic agent is immense. Rigorous clinical trials are needed to confirm its efficacy and safety in other forms of progressive pulmonary fibrosis, such as SSc-ILD, uILD, and post-COVID-19 fibrosis, to support regulatory approval and expand treatment options for these patients.
3. Advancement Toward Personalized Medicine: The future of IPF therapy lies in moving from a one-size-fits-all approach to personalized medicine. Research should focus on identifying and validating predictive biomarkers—whether genetic (e.g., CYP1A2 genotype), proteomic (e.g., plasma levels of CCL18), or clinical—that can help clinicians select the right drug for the right patient, predicting who is most likely to respond to Pirfenidone and who is at the highest risk of toxicity. This will allow for the maximization of benefit and minimization of harm, further refining the role of Pirfenidone in the fight against fibrotic lung disease.

Works cited

1. Pirfenidone: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 29, 2025, https://go.drugbank.com/drugs/DB04951
2. Pirfenidone: MedlinePlus Drug Information, accessed July 29, 2025, https://medlineplus.gov/druginfo/meds/a615008.html
3. Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease, accessed July 29, 2025, https://www.atsjournals.org/doi/full/10.1165/rcmb.2019-0328TR
4. Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial | Thorax, accessed July 29, 2025, https://thorax.bmj.com/content/78/9/882
5. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis - ERS Publications, accessed July 29, 2025, https://publications.ersnet.org/content/errev/24/135/58
6. Esbriet® (pirfenidone) - Information for Patients - Genentech, accessed July 29, 2025, https://www.gene.com/patients/medicines/esbriet
7. Pirfenidone - Wikipedia, accessed July 29, 2025, https://en.wikipedia.org/wiki/Pirfenidone
8. What is the mechanism of Pirfenidone? - Patsnap Synapse, accessed July 29, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-pirfenidone
9. go.drugbank.com, accessed July 29, 2025, https://go.drugbank.com/drugs/DB04951#:~:text=By%20suppressing%20TGF%2D%CE%B21%2C%20pirfenidone,synthesis%20and%20extracellular%20matrix%20production.
10. InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in ..., accessed July 29, 2025, https://www.fiercebiotech.com/biotech/intermune-reports-phase-3-ascend-trial-results-of-pirfenidone-idiopathic-pulmonary-fibrosis
11. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials | European Respiratory Society, accessed July 29, 2025, https://publications.ersnet.org/content/erj/47/1/243
12. Long-term clinical and real-world experience with pirfenidone in the ..., accessed July 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9487763/
13. Safety & Tolerability - Esbriet® (pirfenidone), accessed July 29, 2025, https://www.esbriethcp.com/side-effects/safety-tolerability.html
14. Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their ..., accessed July 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6019423/
15. Pharmacological basis of the antifibrotic effects of pirfenidone: Mechanistic insights from cardiac in-vitro and in-vivo models, accessed July 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9530045/
16. 022535Orig1s000 - accessdata.fda.gov, accessed July 29, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000ClinPharmR.pdf
17. Antifibrotic for treatment of idiopathic pulmonary fibrosis - HTA Database, accessed July 29, 2025, https://database.inahta.org/article/19778
18. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments | Journal of Managed Care & Specialty Pharmacy - JMCP.org, accessed July 29, 2025, https://www.jmcp.org/doi/10.18553/jmcp.2017.23.3-b.s5
19. Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic ..., accessed July 29, 2025, https://mayoclinic.elsevierpure.com/en/publications/cost-effectiveness-of-the-anti-fibrotics-for-the-treatment-of-idi
20. Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France - Taylor & Francis Online, accessed July 29, 2025, https://www.tandfonline.com/doi/pdf/10.1080/20016689.2019.1626171
21. Use of pirfenidone in fibrotic interstitial lung diseases and ... - Frontiers, accessed July 29, 2025, https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1411279/full
22. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis ..., accessed July 29, 2025, https://www.atsjournals.org/doi/10.1164/rccm.201706-1301OC
23. 022535Orig1s000 - accessdata.fda.gov, accessed July 29, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000SumR.pdf
24. 022535Orig1s000 - accessdata.fda.gov, accessed July 29, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000ChemR.pdf
25. Pirfenidone, orally active anti-inflammatory antifibrotic agent (CAS 53179-13-8) (ab141425), accessed July 29, 2025, https://www.abcam.com/en-us/products/biochemicals/pirfenidone-orally-active-inflammatory-antifibrotic-agent-ab141425
26. Pirfenidone | CAS 53179-13-8 | SCBT - Santa Cruz Biotechnology, accessed July 29, 2025, https://www.scbt.com/p/pirfenidone-53179-13-8
27. www.tga.gov.au, accessed July 29, 2025, https://www.tga.gov.au/sites/default/files/auspar-pirfenidone-160809-pi.docx
28. pirfenidone | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed July 29, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7532
29. Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease, accessed July 29, 2025, https://www.atsjournals.org/doi/10.1165/rcmb.2019-0328TR
30. go.drugbank.com, accessed July 29, 2025, https://go.drugbank.com/drugs/DB04951#:~:text=It%20is%20suggested%20that%20the,effects%2C%20leading%20to%20antifibrotic%20effects.&text=Pirfenidone%20attenuates%20the%20production%20of,idiopathic%20pulmonary%20fibrosis%20(IPF).
31. Real world experience on the effectiveness and safety of pirfenidone ..., accessed July 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10642852/
32. Pirfenidone (AMR 69, CAS Number: 53179-13-8) | Cayman Chemical, accessed July 29, 2025, https://www.caymanchem.com/product/13986/pirfenidone
33. Pirfenidone (Esbriet) | Davis's Drug Guide - Nursing Central, accessed July 29, 2025, https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110422/all/pirfenidone?q=instruction
34. Pirfenidone: Package Insert / Prescribing Information - Drugs.com, accessed July 29, 2025, https://www.drugs.com/pro/pirfenidone.html
35. Pirfenidone - Wikiwand, accessed July 29, 2025, https://www.wikiwand.com/en/articles/Pirfenidone
36. Idiopathic Pulmonary Fibrosis (IPF) Completed Phase 3 Trials for Pirfenidone (DB04951), accessed July 29, 2025, https://go.drugbank.com/indications/DBCOND0031843/clinical_trials/DB04951?phase=3&status=completed
37. Pirfenidone for Idiopathic Pulmonary Fibrosis | American Journal of Respiratory and Critical Care Medicine, accessed July 29, 2025, https://www.atsjournals.org/doi/full/10.1164/rccm.201602-0258RR
38. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study, accessed July 29, 2025, https://publications.ersnet.org/content/erjor/4/4/00084-2018
39. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials | BMJ Open Respiratory Research, accessed July 29, 2025, https://bmjopenrespres.bmj.com/content/3/1/e000105
40. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis - PMC, accessed July 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9488585/
41. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study, accessed July 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6194203/
42. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis | Request PDF - ResearchGate, accessed July 29, 2025, https://www.researchgate.net/publication/281587757_All-case_post-marketing_surveillance_of_1371_patients_treated_with_pirfenidone_for_idiopathic_pulmonary_fibrosis?_tp=eyJjb250ZXh0Ijp7InBhZ2UiOiJzY2llbnRpZmljQ29udHJpYnV0aW9ucyIsInByZXZpb3VzUGFnZSI6bnVsbCwic3ViUGFnZSI6bnVsbH19
43. Pirfenidone Viatris | European Medicines Agency (EMA), accessed July 29, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/pirfenidone-viatris
44. Idiopathic Pulmonary Fibrosis (IPF) Treatment | Esbriet® (pirfenidone), accessed July 29, 2025, https://www.esbriet.com/
45. Esbriet® (pirfenidone) | Idiopathic Pulmonary Fibrosis (IPF) Treatment, accessed July 29, 2025, https://www.esbriethcp.com/
46. www.esbriethcp.com, accessed July 29, 2025, https://www.esbriethcp.com/side-effects/important-safety-information.html#:~:text=Moderate%20or%20strong%20inhibitors%20of,exposure%20and%20efficacy%20of%20Esbriet.
47. Pirfenidone Interactions Checker - Drugs.com, accessed July 29, 2025, https://www.drugs.com/drug-interactions/pirfenidone.html
48. Quality of Life Study in Participants With IPF Under Pirfenidone Treatment | ClinicalTrials.gov, accessed July 29, 2025, https://clinicaltrials.gov/study/NCT03115619
49. Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis - Becaris Publishing, accessed July 29, 2025, https://becarispublishing.com/doi/10.2217/cer-2020-0084
50. Anti-fibrotic therapy in the treatment of IPF: Ongoing concerns and current practices, accessed July 29, 2025, https://www.mayoclinic.org/medical-professionals/pulmonary-medicine/news/anti-fibrotic-therapy-in-the-treatment-of-ipf-ongoing-concerns-and-current-practices/mac-20438808
51. pmc.ncbi.nlm.nih.gov, accessed July 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10398274/#:~:text=For%20this%20study%20cohort%2C%20total,stay%20%C3%97%201%2C174%20hospital%20stays)..&sa=D&source=editors&ust=1753775940492067&usg=AOvVaw1UrAl5nvhZD3pTzjFpVh7L)
52. Strategies to Manage Costs in Idiopathic Pulmonary Fibrosis, accessed July 29, 2025, https://www.ajmc.com/view/strategies-to-manage-costs-in-idiopathic-pulmonary-fibrosis-article
53. Humanistic and Economic Burden Associated with Idiopathic Pulmonary Fibrosis (IPF): Summary of Evidence from Systematic Literature - ISPOR, accessed July 29, 2025, https://www.ispor.org/docs/default-source/euro2024/20240611bi-poster-1-ispor-europe-2024ipffinal-digital-1146126-pdf.pdf?sfvrsn=a05ec1f2_0
54. (PDF) Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States - ResearchGate, accessed July 29, 2025, https://www.researchgate.net/publication/357716041_Cost-effectiveness_of_the_anti-fibrotics_for_the_treatment_of_idiopathic_pulmonary_fibrosis_in_the_United_States
55. Pirfenidone for treating idiopathic pulmonary fibrosis - NICE, accessed July 29, 2025, https://www.nice.org.uk/guidance/ta504/documents/final-appraisal-determination-document
56. Full article: Cost-effectiveness of pirfenidone compared to all ..., accessed July 29, 2025, https://www.tandfonline.com/doi/full/10.1080/20016689.2019.1626171
57. (PDF) Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium - ResearchGate, accessed July 29, 2025, https://www.researchgate.net/publication/338592867_Cost-Effectiveness_Analysis_of_Nintedanib_Versus_Pirfenidone_in_Idiopathic_Pulmonary_Fibrosis_in_Belgium
58. Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium - PubMed, accessed July 29, 2025, https://pubmed.ncbi.nlm.nih.gov/31939146/
59. Systemic Sclerosis Associated Interstitial Lung Disease Unknown Status Phase 3 Trials for Pirfenidone (DB04951) - DrugBank, accessed July 29, 2025, https://go.drugbank.com/indications/DBCOND0158009/clinical_trials/DB04951?phase=3&status=unknown_status
60. Esbriet (pirfenidone) - Roche, accessed July 29, 2025, https://www.roche.com/solutions/pharma/productid-6c2ee193-7a4e-4d73-b48d-6c8fa1179a11
61. Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review - MDPI, accessed July 29, 2025, https://www.mdpi.com/1422-0067/24/9/7849
62. A systematic review and meta-analysis of the clinical benefits and adverse reactions of anti-fibrotics in non-IPF progressive fibrosing ILD - PubMed, accessed July 29, 2025, https://pubmed.ncbi.nlm.nih.gov/39089077/
63. Full article: Antifibrotic therapy in progressive pulmonary fibrosis: a review of recent advances - Taylor & Francis Online, accessed July 29, 2025, https://www.tandfonline.com/doi/full/10.1080/17476348.2024.2375420
64. Efficacy and safety of combination therapy with ... - Frontiers, accessed July 29, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1301923/full
65. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis - PMC, accessed July 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6092682/
66. Combination Therapy and the Start of a New Epoch for Idiopathic Pulmonary Fibrosis? | American Journal of Respiratory and Critical Care Medicine, accessed July 29, 2025, https://www.atsjournals.org/doi/10.1164/rccm.201709-1939ED
67. Weekly Rundown: FDA probes Sarepta after third death in gene therapy trial, accessed July 29, 2025, https://www.drugdiscoverynews.com/weekly-rundown-fda-probes-sarepta-after-third-death-in-gene-therapy-trial-16516